Search Abstracts Program

Session 65   Poster Session Antiretroviral Chemotherapy in Resource Limited Settings 4:30-6:30 pm 4E-F

Click on the to view the poster for an abstract.

456-W.	Total Lymphocyte Count (TLC) as a Surrogate for CD4 Count to Initiate and Monitor HAART in Resource-Limited Countries T. Flanigan*1, A. Mahajan1 , N. Kumarasamy2, K. Mayer1, C. Carpenter1, and S. Solomon2 1Brown Univ. Med. Sch., Providence, RI and 2YRG Care, Chennai, India Add to Itinerary
457-W.	Review of Antiretroviral Therapy in the Private Sector in Nairobi, Kenya D. Macharia*1, G. Lule2, D. Silverstein2, G. Tesfaledet3, S. Patel4, D. M. Owili3, L. W. Chang5,6, L. Nganga1, K. M. DeCock1, and P. J. Weidle6 1CDC-Kenya, Nairobi; 2Nairobi Hosp., Kenya; 3Aga Kahn Hosp., Nairobi, Kenya; 4M.P. Shah Hosp., Nairobi, Kenya; 5Emory Univ. Sch. of Med. and Rollins Sch. of Publ. Health, Atlanta, GA; and 6CDC, Atlanta, GA Add to Itinerary
458-W.	Long-Term Evaluation (15 Months) of ddI, 3TC and Efavirenz Once-Daily Regimen in Naïve Patients in Senegal: ANRS 12-04/IMEA 011 Study R. Landman*1, S. Thiam2, A. Canestri1, E. Delaporte3, S. Mboup2, M. Vray4, C. Dalban4, S. Badiane2, P. Sow2, A. F. Niang2 , P. M. Gueye2, I. Lanièce2, J. P. Coulaud1 , P. M. Girard1, and I. Ndoye2 1IMEA, Paris, France; 2PNLS, Dakar, Senegal; 3IRD, Montpellier, France; and 4INSERM SC4, France Add to Itinerary
459-W.	First Evaluation of d4T, ddI, and Efavirenz in Antiretroviral-Naïve Patients in Senegal: ANRS 12-06 / IMEA 012 Study R. Landman*1, A. Canestri1, S. Thiam2, E. Delaporte3, S. Mboup2, M. Vray4, C. Dalban4, S. Badiane2, P. Sow2 , A. F. Niang2 , P. M. Gueye2, I. Lanièce2 , J. P. Coulaud1, P. M. Girard1, and I. Ndoye2 1IMEA, Paris, France; 2PNLS, Dakar, Senegal; 3IRD, Montpellier, France; and 4INSERM SC4, France Add to Itinerary
460-W.	The Senegalese Government HAART Initiative: An 18-Month Follow-Up Study of Feasibility, Effectiveness, Adherence, Toxicity and Viral Resistance C. Laurent1, N. Diakhate2, N. Fatou Ngom2, P. Sow2, M. Faye2, M. Gueye3, I. Lanièce1, C. Toure Kane4, F. Liegeois1, S. Mboup4, S. Badiane4 , I. Ndoye5, and E. Delaporte*1 1IRD and Univ.of Montpellier, France; 2Fann Univ. Hosp., Dakar, Senegal; 3Military Hosp., Dakar, Senegal; 4Le Dantec Univ.Hosp., Dakar, Senegal; and 5Natl. AIDS Program, Dakar, Senegal. Add to Itinerary
461-W.	Genotypic and Phenotypic Analyses of Drug Susceptibility in HIV-1 Isolates from Drug-Naïve Patients in Nigeria S. M. Agwale*1, C. Zeh2, E. Paxinos3, L. Odama1, D. Pienazek2, C. Wambebe1, M. L. Kalish2, and R. Ziermann3 1Natl. Inst. for Pharmaceutical Res. and Development, Abuja, Nigeria; 2CDC, Atlanta, GA; 3ViroLogic Inc., South San Franciso, CA; and 4Bayer Diagnostics, Emeryville, CA Add to Itinerary
462-W.	Survival of Persons with HIV Disease following Antiretroviral Therapy in Southern India N. Kumarasamy*1, K. Mayer2 , T. Flanigan2, R. Hemalatha1, C. Carpenter2, S. P. Thyagarajan3, and S. Solomon1 1YRG Ctr. for AIDS Res. and Education, Chennai, India; 2Brown Univ., Providence, RI; and 3Univ. of Madras, Chennai, India Add to Itinerary
463-W.	Safety, Tolerability, and Efficacy of Nevirapine-Based HAART amongst Antiretroviral Naïve HIV-1-Infected Patients in India S. Pujari*1, E. Naik2, A. Patel3, and S. Bhagat1 1Ruby Hall Clin., Pune, India; 2Univ. of South Florida, Tampa; and 3Infectious Diseases, Ahmedabad, India Add to Itinerary
464-W.	Molecular Mechanism of DAPD Anti-HIV Activity against AZT and 3TC Mutants-Molecular Modeling Studies of HIV-1 RT Y. H. Chong1, R. F. Schinazi2, and C. K. Chu*1 1Univ. of Georgia, Athens and 2Emory Univ. Sch. of Med., VA Med. Ctr., Decatur, GA Add to Itinerary

---